

# The Max Perutz Fund

(A company limited by guarantee)

## ANNUAL REPORT AND FINANCIAL STATEMENTS

For the year ending 30 September 2022

Charity Commission number 1129597

Company number 06876186

# The Max Perutz Fund (a company limited by guarantee)

<b>Contents</b>	<b>Page Numbers</b>
Legal and administrative information	2
Report of the Trustees	3 - 10
Report of the Auditors	11 - 13
Statement of financial activities	14
Charity balance sheet	15
Notes forming part of the financial statements	16 - 24

# The Max Perutz Fund (a company limited by guarantee)

## Legal and administrative information

**Charity registration number:** 1129597

**Company registration number:** 6876186

### **Directors and**

<b>Trustees:</b>	Dr Kevin Moreton	24/11/15 – present
	Dr Jan Löwe	17/05/18 – present
	Dr Liz Miller	13/08/18 – present
	Dr Leo James	28/03/19 – present
	Dr Anne Bertolotti	05/11/20 – present

**Secretary:** Mrs Josie Gowler FCA 18/04/18 – present

**Registered Office:** MRC Laboratory of Molecular Biology  
Francis Crick Avenue  
Cambridge Biomedical Campus  
Cambridge  
CB2 0QH

**Auditors:** **Price Bailey LLP:**  
Tennyson House  
Cambridge Business Park  
Cambridge  
CB4 0WZ

**Bankers:** **Lloyds Bank PLC:**  
3 Sidney Street  
Cambridge  
CB2 3BU

**Solicitors:** **Harrison Clark Rickerbys Limited:**  
50-60 Station Road  
Cambridge  
CB1 2JH

# The Max Perutz Fund (a company limited by guarantee)

## Report of the Trustees (incorporating a Directors' Report) for the year ended 30 September 2022

The Trustees, who are also directors of the charity for the purposes of the Companies Act, submit their annual report and the audited financial statements for the year ended 30<sup>th</sup> September 2022. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the annual report and financial statements of the charity.

The charity is a charitable company limited by guarantee and was set up on 14<sup>th</sup> April 2009. It is governed by a memorandum and articles of association. Its objects are the promotion and advancement of education and research in molecular science and allied biomedical fields including by the award of prizes for scientific achievement or potential.

### Structure, governance and management

The Max Perutz Fund was established as a charitable company in April 2009, to replace the previous charity of the same name, which was an unincorporated charity (Charity Commission number 280871). This had been established in 1980 to mark the retirement of Dr Max Perutz as the first chairman of the MRC Laboratory of Molecular Biology. The previous charity was subsequently merged into the new charity with effect from 2 December 2010, the funds having transferred in January 2010.

The charity is closely associated with the MRC Laboratory of Molecular Biology (LMB), and the articles make specific provision for the Director of the LMB to be a Trustee, if he/she so wishes. Dr Jan Löwe, currently Director of the LMB, is chairman of the Trustees.

The Trustees are the members of the charity, and new Trustees are appointed by the current Trustees in line with the articles. It is the Trustees' intention that they should represent a range of scientific expertise.

Mrs Josie Gowler, the LMB's Head of Finance and Research Contracts, acts as company secretary, without remuneration from the charity.

The Trustees ensure they comply with the Charity Governance Code for smaller charities as follows:

- Organisational purpose: the Trustees are clear about the charity's aims and ensure that these are being delivered effectively and sustainably via board meetings and informal discussions between meetings. Further information is shown in the section 'Objectives and Public Benefit' below.
- Leadership: Dr Jan Löwe, currently Director of the LMB, is chairman of the Trustees and the board leads the achievement of the charity's aims and values.
- Integrity: Trustees act with integrity at all times, as monitored at board meetings. Further information on managing potential conflicts of interest is detailed on page 4.
- Decision-making, risk and control: the Trustees make all the decisions in respect of the charitable company, which does not have any employees. The Trustees meet formally at least twice a year to agree strategy and areas of activity for the Fund, including the awards of grants and prizes, together with decisions on investments, reserves and risk management; informal discussions take place as necessary between the formal meetings.
- Board effectiveness and diversity: Board effectiveness is kept under review as part of the meetings of the Trustees and appointments ensure that the Board has an appropriate balance of skills, experience, backgrounds and knowledge to make informed decisions.
- Openness and accountability: the charity is open in its work, which is publicised through its website and at LMB open days.

### Training

All new Trustees are provided with copies of guidance produced by the Charity Commission and of the charity's key documents. These documents, as well as the memorandum and articles of the company, are filed on a shared server along with further information prepared by the company secretary, so that all Trustees can access the



# The Max Perutz Fund (a company limited by guarantee)

guidance easily. An annual discussion session on Trustee responsibilities and on changes to legislation is provided by the Fund's legal advisors.

## Risk Management

The Trustees have considered the major risks to which the charity is exposed, keep these risks under review, and have established systems and procedures to manage these risks. The risk register is reviewed and updated at the Trustees' meetings twice per year.

## Conflicts of interest

The Trustees have established a policy on conflicts of interest and a register of interests. The policy explicitly addresses the handling of financial relationships with the MRC Laboratory of Molecular Biology, since five of the Trustees are also employees of the Medical Research Council, which is part of UK Research and Innovation (UKRI).

## Public benefit statement

The Trustees confirm that, to the best of their knowledge and ability, they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties. The report below gives more details about the specific public benefit from the use of the Max Perutz Fund's charitable funds.

## Objectives and public benefit

The objectives of the charity are the promotion and advancement of education and research in molecular biology and allied biomedical sciences including by the award of prizes for scientific achievement or potential.

The principal activities in support of these objectives are the funding of research, which delivers public benefit through adding to our understanding of the biological processes at the molecular and cellular level and therefore has the potential to help tackle problems in human health and disease. While it is not possible to predict with certainty the outcome of any particular research project, it is the expectation of the Trustees that all the research funded by the charity will lead to publications in the scientific literature. In this way the results of the research are publicly available, and can be freely used by scientists internationally in other research projects. It can be very difficult to track the contributions of an individual research result to a new drug or diagnostic method, but the basic research supported by the Fund is an essential building block for future improvements in health care, to the benefit of the public worldwide.

The Max Perutz Fund supports young scientists to travel to international conferences, to publicise their work, and to benefit from discussions with other scientists to help foster and enhance their research activities.

Lectures arranged by the Max Perutz Fund are open to the public and are advertised on the internet so they are fully accessible.

The Max Perutz Fund also awards prizes in October each year to:

- PhD students in the MRC Laboratory of Molecular Biology who have made significant contributions to research during their studies. These prizes encourage and reward excellence in research, and prize winners are expected to have produced at least one publication, which is a measure of the success of the research project, as well as ensuring wider visibility of the research results.
- Outstanding postdoctoral researchers who have been in post for less than six years.

The Max Perutz Fund is a single charity encompassing separate funds reflecting the aims of the original donors.

The Perutz Fund (designated) is used to fund prizes to young scientists and other approved purposes.

# The Max Perutz Fund (a company limited by guarantee)

The Milstein Fund (designated) funds a studentship or fellowship to enable a young scientist from South America to undertake research at the LMB.

The AstraZeneca Lecture Series (designated) provides a forum where lectures are given by top researchers in biological and medical studies to an interested open public audience.

The Michael Neuberger Studentship (designated) funds PhD studentships for training in fundamental biological and medical research.

The Brenner Postdoc Prize (restricted), sponsored by Royalty Pharma, is a restricted fund for prizes for exceptional postdocs. It has subsequently been renamed the Steitz Postdoc Prize.

The Sangamo Aaron Klug Symposium Fund (restricted) was created through a donation from Sangamo Therapeutics Inc to support the Aaron Klug Symposium which celebrated the life and impact of Aaron Klug. Post-symposium, the remaining funds will be used for academic support.

The Grigg Fellowship Fund (expendable endowment) is to promote closer links between the Garvan Institute of Medical Research in Australia and the LMB.

The Graduate Scientist/Postdoctoral Researcher Fund ('GSA/PAL') (restricted) was created in 2022 and is used to fund networking activities for graduate students and postdoctoral researchers.

Two Funds within the charity are to support the work of Dr Venkatraman (Venki) Ramakrishnan. The first is a restricted donation from the Louis Jeantet Foundation in respect of his award of the Louis Jeantet Prize in 2007. Dr Ramakrishnan's work on the atomic structure and workings of the ribosome, which is responsible for protein synthesis within cells, has the potential to underpin the development of new drugs to help fight antibiotic resistance. The second fund, in the form of an expendable endowment, is from the Agouron Institute.

The Louis Jeantet Prize awarded to Dr Gregory Winter in 1989 was administered originally by the charitable funds of the MRC; in 2012 by mutual agreement it was transferred to the Max Perutz Fund. The fund was intended to be used to underwrite Dr Winter's research on Bicyclic Peptides. The scientific group carrying out this research was discontinued when Dr Winter took up the position of Master of Trinity College Cambridge. During 2015 Dr Winter agreed with the Max Perutz Fund Trustees to donate £150,000 from his Jeantet prize to contribute to the setting up of the Michael Neuberger Studentship at Trinity College Cambridge. On 6 January 2021, the Sir Gregory Winter Jeantet Prize Fund (charity registration no: 1129597-1) became a linked charity to The Max Perutz Fund. Further information on the transfer is disclosed in note 15 to the accounts.

Options continue to be investigated to use Dr Winter's Jeantet funding for opportunities in Synthetic Biology; a research area closely allied to Bicyclic Peptides, or more broadly in the area of Protein and Nucleic Acid Chemistry.

The General Fund can be used to support any of the objectives of the Fund. The Monoclonal Anti-Bodies (MABs) Film forms part of the General Fund. The film is being produced to provide an educational resource to schools and universities explaining the story of how Monoclonal Antibodies were discovered, the research and personalities involved, their development and the importance of their modern day use in the fight against disease and illness.

## Achievements

### *Student Prizes*

Three Max Perutz Student Prizes were awarded in October 2021, as follows:

**Michael Jenkyn-Bedford** – Michael has worked out important mechanisms of DNA replication termination, a fundamental aspect of the lifecycle of cells. During termination, fork convergence leads to the ubiquitination and disassembly of the replisomes. Michael's exciting work on the cryo-EM structure of a terminating yeast replisome

## The Max Perutz Fund (a company limited by guarantee)

and biochemical reconstitutions revealed in detail how the fork's lagging-strand DNA regulates the ubiquitination reaction and blocks disassembly. Michael also showed that an analogous mechanism exists in humans. Michael subsequently moved to a new role as a post-doctoral Research Scientist working with Prof Sebastian Klinge at The Rockefeller University (New York, USA), where he is investigating the process of eukaryotic ribosome biogenesis.

**Silvia Benito Kwiecinski** – Silvia tackled a key question in neurobiology, namely why human brains are comparatively larger than those of other primates. Silvia discovered that the cells in human brain organoids have a different shape to cells in other primate brain organoids. In a series of remarkable experiments she then showed that the shape differences are caused by delayed expression of the transcription factor Zeb2. These novel findings revealed that differences in gene expression cause differently shaped primate brains. Silvia is now a postdoctoral Researcher at Memorial Sloan Kettering Cancer Center in New York.

**Vaithish Velazhahan** – Vaithish solved the structures of yeast GPCRs (G-protein-coupled receptors), which remained poorly understood. Vaithish's highly insightful series of structures revealed that a yeast dimeric GPCR undergoes rearrangements that are remarkably different from those reported for human proteins. These structures not only explain the large library of yeast mutants that had been previously identified, but also raise the possibility of fungal-specific inhibitors that would address a major human disease burden. Vaithish is continuing his research at the LMB.

### *Brenner (subsequently renamed Steitz) Prizes*

Two Postdoc Prizes were awarded in October 2021, as follows:

**Elsje G. (Gisela) Otten** – Gisela worked on an important and challenging problem aimed at identifying the ubiquitin ligase that modifies lipopolysaccharide (LPS), a crucial step in the defence against bacteria that have entered cells. She developed an assay to track the activity of the elusive enzyme and through rigorous biochemical approaches identified RNF213. Gisela's remarkable work identified, for the first time, an E3 ligase that modifies a non-proteinaceous substrate. She has since moved to Amphista in Cambridge, a company which is identifying and advancing novel approaches in targeted protein degradation (TPD).

**Girish Ram Mali** – In an outstanding body of work, Girish Mali discovered a protein he named Shulin that packages dynein motors for delivery to cilia. Girish took the initiative to set up the system that allowed the biochemical isolation of dynein and its associated proteins and discovered Shulin. He went on validating the importance of Shulin genetically, characterised its function and solved the structure of the complex to unravel how dynein is modified by Shulin. Girish has now set up his own laboratory at the University of Bristol's School of Biochemistry where he is working on the assembly of ciliary dyneins.

### Milstein Fellowship

The current Milstein Fellow, Dr Viviane de Souza Rosa, started her Fellowship in May 2021. She did her PhD in Brazil followed by a ten-month working visit to Cambridge during which time she achieved a co-first author publication working on the mechanisms of size regulation in the mouse embryo. She also contributed quite substantially to the project of another PhD student focused on the derivation of a new human stem cell line and is a second author in the manuscript that describes this work. Finally, she helped to set up the conditions to establish a 3D culture of embryonic stem cells. She is continuing with this work at the LMB.

### AstraZeneca Lecture Series

The purpose of the lecture series is for international and national experts in the field of biological and medical research to present their current research. Lectures are open to anyone who is interested in attending.

The following lectures were held during the year:

Professor Michel C Nussenzweig presented the Francis Crick lecture in November 2021 on zoom. The title of the lecture was 'Human immune responses to SARS-CoV-2 infection or vaccination'. Michel is currently the Zanvil A.

## The Max Perutz Fund (a company limited by guarantee)

Cohn and Ralph M. Steinman Chair of Immunology at Rockefeller University, where he has been a member of faculty since 1990. His laboratory researches the innate and adaptive responses of our body's immune systems at a molecular level, using a combination of biochemistry, molecular biology and genetics to do so. His studies on innate immunity are focused on dendritic cells, whilst his work on adaptive immunity looks at B lymphocytes and antibodies to HIV-1 and other viral pathogens including SARS-CoV-2.

The 2021 Cesar Milstein lecture in November 2021 was also held on zoom. Professor Hans Clevers' lecture was on organoids to model human diseases. Hans is a Professor of Molecular Genetics at Utrecht University, in addition to being a principal investigator at the Hubrecht Institute and the Princess Máxima Center for Pediatric Oncology, and an Oncode Investigator. Organoids can be described as 'mini-organs', and help expand our understanding of both healthy or diseased human tissue in vitro. Organoids are now widely used in basic and applied biomedicine, occupying a niche between 'classical' 2D cell lines and animal experimentation.

Professor Carolyn Bertozzi presented the Max Perutz Lecture in March 2022, also over zoom; the lecture was on the subject of therapeutic opportunities in glycoscience. Based at Stanford University, California, Carolyn holds the positions of Anne T. and Robert M. Bass Professor of Chemistry, Baker Family Director of Stanford ChEM-H, and Howard Hughes Medical Institute Investigator. Her research group focuses on the study of glycans and cell surface glycosylation, combining chemical and biological approaches to better understand the chemistry of cellular communication. Carolyn's research has brought the field of glycobiology into the mainstream and provided important insights into cellular function. Carolyn's research also holds vast clinical importance within immuno-oncology for the development of drug discovery and the therapeutic targeting of cancer, inflammation, bacterial infection, tuberculosis and most recently COVID-19.

In May 2022, Professor Alice Ting presented the John Kendrew Lecture over zoom. Alice's talk, 'Chemogenetic and optogenetic technologies for probing molecular and cellular networks', gave a brief account of PL method development, including directed evolution of the PL enzymes APEX and TurboID, and then described new efforts to extend PL to RNA and proteome trafficking. In the second part of the talk she explained recent work on the development of scalable, single-cell molecular recorders of past cellular events, and the application of these recorders to neuroscience and mitochondrial biology. Alice Ting is Professor of Genetics, Biology and, by courtesy, Chemistry at Stanford University, a post she has held for the past eight years. Since 2017 she has also been a Chan Zuckerberg Biohub investigator. Her group is dedicated to the development of new technologies to map molecules, cells and functional circuits and applying these to better understand signalling in mitochondria and in the mammalian brain.

Uğur Şahin and Özlem Türeci, of BioNTech, delivered the 2022 César Milstein Lecture in person and on zoom at the LMB in July 2022. BioNTech was founded in 2008 by Uğur and Özlem, alongside Christoph Huber, with a mission to develop and produce individualised immunotherapies for cancer treatments, using mRNA to incite an antigenic immune response in patients. After reading about COVID-19 in January 2020, Uğur redirected the company to apply this technology to finding a coronavirus vaccine – an endeavour named 'Project Lightspeed'. BioNTech collaborated with US pharmaceutical company, Pfizer, and by November 2020 they had a vaccine candidate which was over 90% effective in protecting people from transmission. Their lecture discussed the applications of messenger RNA (mRNA) technology in vaccines for cancer and COVID-19.

### Michael Neuberger Studentship

A donation was made in 2014/15 to help finance a PhD studentship in the name of Michael Neuberger, jointly with Trinity College Cambridge. In October 2021, the second holder of the Michael Neuberger Studentship, Andrew Zeller, started his PhD at the LMB in Julian Sale's group.

### The Monoclonal Anti-Bodies (MABs) film

The project is supporting the making of an educational film about monoclonal antibodies, arising from the work of Cesar Milstein's work at the Laboratory of Molecular Biology (LMB) and involving filming of current LMB members as well as archive material. The MABs film progressed during the year, with an edited rough cut of the film completed in May 2022.

# The Max Perutz Fund (a company limited by guarantee)

## Sangamo Aaron Klug Symposium Fund

Sangamo Therapeutics Inc supported the Aaron Klug Memorial Symposium which was held in May 2022. Alumni, colleagues, family and friends were welcomed to the LMB to celebrate the life and work of Aaron Klug. The programme included talks by many of Aaron's former colleagues, scientists influenced by his work, and his family.

## Other

A summer student was sponsored by the Max Perutz Fund to take up a placement in the LMB, as part of ongoing initiatives to widen participation in science.

A book, *Ahead of the Curve*, was produced by the LMB to showcase the scientific achievements of pioneering women scientists at the LMB, describing the work they have done within the context of their lives outside the lab. The book has achieved the goal of celebrating women at the LMB over the years, raising awareness of their science and how they juggled this with their personal lives. The Max Perutz Fund is benefitting from all proceeds from the sale of the book.

The LMB again produced themed Christmas cards in 2021; all proceeds from the sale of these were passed to the Max Perutz Fund.

Further information on these initiatives is given in note 14 to the accounts.

## **Fundraising**

No fundraising is carried out on the Max Perutz Fund's behalf by any third party. Information on donating to the fund is included on the Max Perutz Fund's website and donors are also able to donate at LMB open days; no fundraising approaches are made directly to the public. The fund has not received any complaints related to its fundraising but if it ever did receive such a complaint this would be reviewed immediately by the Trustees and treated with the utmost seriousness.

## **Financial Review**

During the year, income for the charity amounted to £219,385 (2021 - £342,862). Donations from individuals totalled £10,641 (2021 - £80,448), and donations from corporate donors amounted to £53,006 (2021 - £16,919). Gift aid income of £560 (2021 - £19,073) has been recognised with £560 (2021 - £19,060) included within debtors at the year end. (In addition, in 2021 a legacy of £100,000 was received.)

Resources expended in the year amounted to £92,764 (2021 - £54,456).

The market value of investments fell by £344,701 in the year to 30 September 2022 (2021 – increase of £608,428), with investments now standing at £2,852,106 (2021 - £2,896,807), the drop being due to general market conditions after the 'mini budget' of September 2022.

The charity has strong reserves and has not needed to curtail any activities due to the financial impact of the covid-19 pandemic or more recent current market conditions. The Trustees keep activities under review in light of the volatility in the financial markets.

The Trustees have developed an investment policy which reflects the different purposes of the individual funds. Unless the donor expects the donation to be spent in full over a number of years, the priority is to retain the capital value of the donation. For funds which constitute an expendable endowment, the Trustees seek to balance protecting the capital value with maximising income.



# The Max Perutz Fund (a company limited by guarantee)

## Reserves Policy

The Fund has no long-term obligations and only makes awards if funds to cover the full value of the award are available. For expendable endowment funds, the Trustees set a reserve which balances the need to sustain the fund and generate income to meet the objectives of the charity.

## Plans for the coming year

The Trustees will continue to support and encourage scientists in the early stages of their career, through the provision of fellowships, exchange visits, attendance at meetings and the awarding of prizes. It will also continue to foster the aims of the individual restricted funds. As funds permit, the Trustees will consider providing stipends for LMB PhD students who are ineligible for full MRC funding because of their nationality.

Brenner (now renamed Steitz) postdoctoral prizes were awarded again in October 2022.

The Max Perutz Fund created a new award (named the Eileen Southgate prize) for scientific facilities and support staff at the LMB to complement the existing student and postdoctoral prizes; the first awards were made in October 2022.

The MABs film, 'The Library of All Possible Things' is now in post-production and this will be progressed during the coming year with the film due to be completed in 2023. The footage will be used at the LMB open day in July 2023.

Graduate and Postdoctoral networking events will be arranged and will be funded by the GSA/PAL fund.

The Women at LMB symposium (rescheduled from November 2020 due to the covid-19 pandemic) was held in November 2022. Sales of Ahead of the Curve are continuing.

The LMB has produced themed Christmas cards again in 2022 with all proceeds from the sale of these being allocated to the Max Perutz Fund.

The Grigg Fellowship continues to be promoted through the MRC Laboratory of Molecular Biology.

# The Max Perutz Fund (a company limited by guarantee)

## Trustees' responsibilities in relation to the financial statements

The trustees (who are also directors of the Max Perutz Fund for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Practice).

Company law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP FRS102;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditor is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

In preparing this report the Trustees have taken advantage of the Small Companies exemptions provided by Section 415A of the Companies Act 2006.

Approved by the Trustees on 27/3/23 and signed on their behalf by



**Dr Jan Löwe**  
**Chairman of the Max Perutz Fund**

# The Max Perutz Fund (a company limited by guarantee)

## Independent Auditor's Report to the Members of The Max Perutz Fund

### Opinion

We have audited the financial statements of The Max Perutz Fund (the 'charitable company') for the year ended 30 September 2022 which comprise the Statement of Financial Activities incorporating Income and Expenditure Account, the Balance sheet and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 30 September 2022, and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

### Other information

The other information comprises the information included in the trustees' annual report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial



# The Max Perutz Fund (a company limited by guarantee)

statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

## Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the trustees' report (incorporating the directors' report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the directors' report included within the trustees' report has been prepared in accordance with applicable legal requirements.

## Matters on which we are required to report by exception

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report included within the trustees' report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate and proper accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the trustees' report and from the requirement to prepare a strategic report.

## Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 10, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

## Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above to detect material misstatements in respect of irregularities,

## The Max Perutz Fund (a company limited by guarantee)

including fraud. The extent to which our procedures are capable of detecting irregularities including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the charitable company and how it operates and considered the risk of the charitable company not complying with the applicable laws and regulations including fraud in particular those that could have a material impact on the financial statements. This included those regulations directly related to the financial statements. In relation to the charity this included data protection and financial reporting.

The risks were discussed with the audit team and we remained alert to any indications of non-compliance throughout the audit. We carried out specific procedures to address the risks identified. These included the following:

- Management override: We reviewed systems and procedures to identify potential areas of management override risk. In particular, we carried out testing of journal entries and other adjustments for appropriateness.
- Reviewing minutes of Trustee Board meetings and correspondence with the Charity Commission, agreeing the financial statement disclosures to underlying supporting documentation, enquiries of management including those responsible for the key regulations and a review of the risk management processes and procedures in place. We have also reviewed the procedures in place for the reporting of any incidents to the Trustee Board including serious incident reporting of these matters as necessary with the Charity Commission.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our auditor's report.

### Use of our report

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members for our audit work, for this report, or for the opinions we have formed.



**Helena Wilkinson FCA (Senior Statutory Auditor)**

For and on behalf of Price Bailey LLP  
Chartered Accountants  
Statutory Auditors  
Tennyson House  
Cambridge  
CB4 0WZ  
United Kingdom

Date: 27 March 2023

The MAX Perutz Fund ( a company limited by guarantee)

**Statement of Financial Activities (including summary income and expenditure account) for the year ended 30 September 2022**

		Unrestricted Funds	Restricted Funds	Expendable Endowment Funds	Total Year 01/10/21 to 30/09/22	Total Year 01/10/20 to 30/09/21
	Note	£	£	£	£	£
<b>Income:</b>						
Donations and legacies	3	28,701	35,506	0	64,207	216,440
Investment Income	4	90,559	47,657	16,790	155,006	126,253
Trading income	14	172	0	0	172	169
<b>Total Income</b>		<u>119,432</u>	<u>83,163</u>	<u>16,790</u>	<u>219,385</u>	<u>342,862</u>
<b>Expenditure on:</b>						
Charitable Activities		70,905	21,856	0	92,761	54,418
Trading Activities		3	0	0	3	38
<b>Total Expenditure</b>	5	<u>70,908</u>	<u>21,856</u>	<u>0</u>	<u>92,764</u>	<u>54,456</u>
Net Gains/(Losses) on Investments		(201,377)	(105,985)	(37,339)	(344,701)	608,428
<b>Net (Expenditure) / Income</b>		<u>(152,853)</u>	<u>(44,678)</u>	<u>(20,549)</u>	<u>(218,080)</u>	<u>896,834</u>
Transfers between funds		0	0	0	0	0
<b>Net movement in funds</b>		<u>(152,853)</u>	<u>(44,678)</u>	<u>(20,549)</u>	<u>(218,080)</u>	<u>896,834</u>
Fund Balances brought forward at 01 October 2021		<u>2,031,465</u>	<u>1,032,144</u>	<u>368,443</u>	<u>3,432,052</u>	<u>2,535,218</u>
Fund Balances carried forward at 30 September 2022		<u>1,878,612</u>	<u>987,466</u>	<u>347,894</u>	<u>3,213,972</u>	<u>3,432,052</u>

All of the above results are derived from continuing activities.

The Statement of Financial Activities includes all gains and losses recognised in the year and includes the position of its connected charity, the Sir Gregory Winter Jeantet Prize Fund. See note 15 for further information.

The notes on pages 16 to 24 form part of these financial statements.

**The Max Perutz Fund** ( a company limited by guarantee)

Company Number 6876186

**Balance sheet as at 30th September 2022**

	Notes	30/09/2022 £	30/09/2021 £
<b>Fixed Assets</b>			
Investments	9	2,852,106	2,896,807
<b>TOTAL FIXED ASSETS</b>		<u>2,852,106</u>	<u>2,896,807</u>
<b>Current Assets</b>			
Debtors: amounts falling due within one year	10	560	119,060
Cash at bank and in hand		382,021	429,539
<b>TOTAL CURRENT ASSETS</b>		<u>382,581</u>	<u>548,599</u>
<b>Creditors: amounts falling due within one year</b>	11	(20,715)	(13,354)
<b>Net current assets</b>		<u>361,866</u>	<u>535,245</u>
<b>Net Assets</b>		<u>3,213,972</u>	<u>3,432,052</u>
<b>Funds of the charity</b>			
<b>Unrestricted Funds</b>			
General Funds		1,020,607	1,096,930
Designated Funds		858,005	934,535
		<u>1,878,612</u>	<u>2,031,466</u>
<b>Restricted Funds</b>			
Restricted Funds		987,466	1,032,144
Expendable Endowment Funds		347,894	368,443
		<u>1,335,360</u>	<u>1,400,588</u>
<b>Total Funds</b>	12	<u>3,213,972</u>	<u>3,432,052</u>

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the trustees on 27/3/23 and signed on their behalf by



Dr Jan Löwe  
Chairman of the Max Perutz Fund

The notes on pages 16 to 24 form part of these financial statements.

## **1 Accounting Policies**

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows:

### **1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2016) - (Charities SORP (FRS 102), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) and the Companies Act 2006.

The Charity constitutes a public benefit entity as defined by FRS 102. Assets and Liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

The financial statements are presented in sterling, which is the functional currency of the charity and are rounded to the nearest pound.

The Charity is registered in England and Wales. The address of the Charity's registered office is shown on page 2.

### **1.2 Cashflow Exemption**

The company, being a company of small size within the meaning of the Companies Act 2006, has used the exemption provided by the early adoption of the SORP Bulletin issued in February 2016 under which it is not required to include a cashflow statement as part of the financial statements.

### **1.3 Going Concern**

The trustees have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. For this reason they continue to adopt the going concern basis in the preparation of the financial statements.

### **1.4 Legal Status**

There is no share capital as the company is limited by guarantee. Each member has guaranteed an amount, not exceeding £10, towards the company's liabilities in the event of a winding up.

### **1.5 Fund Accounting**

General Funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds comprise unrestricted funds that have been set aside by the trustees for particular purposes. The aim and use of each designated fund is set out in the notes to the financial statements. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by the donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Expendable endowments managed by the Max Perutz Fund are Expendable Endowments and are to be held by the charity for a lengthy but not permanent period. The Expendable Endowments are the result of donations which will be spent in accordance with the objectives of the charity, and any income arising from the investment of the Endowments are attributed as additions to the Endowments. Any investment management charges and legal advice relating to the Endowments are charged against the funds.

## **1.6 Income**

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received and the amount can be measured reliably.

For legacies, entitlement is taken on a case by case basis as the earlier of the date on which the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the charity that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution. If the legacy is in the form of an asset other than cash or an asset listed on a recognised stock exchange, recognition is subject to the value of the asset being able to be reliably measured and title to the asset has passed to the charity. Where legacies have been notified or the charity is aware of the granting of probate, and the criteria for income recognition has not been met, then the legacy is treated as a contingent asset and disclosed if material.

No amounts are included in the financial statements for services donated by volunteers.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

## **1.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to make a payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably. All expenditure is accounted for on an accruals basis. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of the resources.

## **1.8 Fixed assets investments**

Quoted investments are valued at the balance sheet date at market value. Revaluation gains or losses are recognised in the statement of financial activities, and attributed to the fund for which the investments are held.

## **1.9 Cash at Bank and in hand**

Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

## **1.10 Creditors**

Creditors are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors are normally recognised at their settlement amount after allowing for any trade discounts due.

## **1.11 Financial Instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, which, in the case of the charity is at cost for creditors and debtors and market value for investments.

2 Judgements and key sources of estimation uncertainty

In the application of the Charity's accounting policies, which are described in note 1, the Trustees are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates' associated assumptions are based on historical experience and other factors considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

The Trustees do not consider there are any critical accounting judgements or key sources of estimation uncertainty requiring disclosure.



# The Max Perutz Fund (a company limited by guarantee)

## 3 Donations and legacies

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Individuals	10,641	80,448
Legacies	0	100,000
Gift Aid	560	19,073
Corporate Donors	53,006	16,919
	<u>64,207</u>	<u>216,440</u>

Of the above donations, £35,506 related to restricted funds and the remainder to unrestricted funds; in 2021 £15,441 related to restricted funds and the remainder to unrestricted funds.

## 4 Investment Income

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Interest Receivable	8	18
Dividends received from Investments	154,998	126,235
	<u>155,006</u>	<u>126,253</u>

Investment income for 2022 was £155,006 (2021 - £126,253) of which £90,559 (2021 - £73,159) was attributable to unrestricted funds, £47,657 (2021 - £39,127) was attributable to restricted funds and £16,790 (2021 - £13,967) was attributable to restricted expendable endowments.

## 5a Analysis of Expenditure - Current Year

	Activites Undertaken Directly £	Support Costs (Note 6) £	Total Funds £
Promotion and advancement of education and research	84,816	7,945	92,761
Trading activities	3	0	3
	<u>84,819</u>	<u>7,945</u>	<u>92,764</u>

## 5b Analysis of Expenditure - Prior Year

	Activites Undertaken Directly £	Support Costs (Note 6) £	Total Funds £
Promotion and advancement of education and research	48,620	5,798	54,418
Trading activities	38	0	38
	<u>48,658</u>	<u>5,798</u>	<u>54,456</u>

Expenditure on charitable activities includes £23,866 (2021 - £5,775) spent from unrestricted funds, £47,042 (2021 - £34,953) spent from designated funds, £21,856 (2021- £13,728) spent from restricted funds and £ Nil (2021 - £ Nil) from restricted expendable endowment funds.

During the year the charity made grants to institutions totaling £40,317 (2021 - £33,953). All grants were payable to the Medical Research Council Laboratory of Molecular Biology (LMB).

No expenditure was incurred on raising funds in 2022 (2021 - £ Nil).



# The Max Perutz Fund (a company limited by guarantee)

## 6 Analysis of Support Costs

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Professional Fees	1,621	1,308
Bank Fees	168	169
Trustee Indemnity Insurance	967	912
Accountancy Services	13	13
Governance Costs (See note 7)	5,176	3,396
	<u>7,945</u>	<u>5,798</u>

## 7 Analysis of Governance Costs

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Audit Fees	<u>5,176</u>	<u>3,396</u>

## 8 Trustees' remuneration

The trustees received no emoluments or reimbursed expenses during the year (2021 - £Nil).

During the year, insurance was purchased to indemnify the Trustees against default on their part. The cost of the insurance amounted to £967 (2021 - £912).

## 9 Fixed asset investments

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Market value as at 1st October	2,896,807	2,188,379
Additions	300,000	100,000
Disposal Proceeds	0	0
Net investments gains / (losses)	(344,701)	608,428
Market value as at 30th September	<u>2,852,106</u>	<u>2,896,807</u>
Historical cost as at 30th September	<u>2,590,854</u>	<u>2,290,854</u>
UK listed investments are represented by:		
Investment trusts and unit trusts	<u>2,852,106</u>	<u>2,896,807</u>
	<u>2,852,106</u>	<u>2,896,807</u>

**The Max Perutz Fund (a company limited by guarantee)**

**10 Debtors: amounts falling due within one year**

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Gift aid accrued income	560	19,060
Legacy accrued income	0	100,000
	<u>560</u>	<u>119,060</u>

**11 Creditors: amounts falling due within one year**

	Total for the Year 01/10/2021 to 30/09/2022 £	Total for the Year 01/10/2020 to 30/09/2021 £
Accruals	<u>20,715</u>	<u>13,354</u>

**12a Statement of Funds - current year**

	At 01/10/2021 £	Income £	Expenditure £	Transfers In/Out £	Investment Gains/ (Losses) £	At 30/09/2022 £
<b>General Fund</b>	1,096,930	57,084	(23,866)	0	(109,541)	1,020,607
<b>Designated Funds</b>						
Perutz Fund	331,290	15,819	(1,500)	0	(33,499)	312,110
Milstein Fund	597,302	25,224	(43,781)	0	(56,096)	522,649
AstraZeneca						
Lecture Series	3,876	21,008	(1,761)	0	(2,241)	20,882
Michael						
Neuberger						
Studentship	2,067	297	0	0	0	2,364
<b>Total</b>	<u>2,031,465</u>	<u>119,432</u>	<u>(70,908)</u>	<u>0</u>	<u>(201,377)</u>	<u>1,878,612</u>
<b>Unrestricted funds</b>						
	<u>2,031,465</u>	<u>119,432</u>	<u>(70,908)</u>	<u>0</u>	<u>(201,377)</u>	<u>1,878,612</u>
<b>Restricted funds</b>						
Steitz (formerly Brenner)						
Postdoc Prize	11,138	34,341	(14,836)	0	(2,970)	27,673
Sangamo Aaron Klug						
Symposium	10,497	173	(6,697)	0	(385)	3,588
GSA/PAL Fund	0	2,606	(178)	0	(236)	2,192
Jeantet						
Ramakrishnan	363,621	16,564	(145)	0	(36,836)	343,204
Jeantet Winter	646,888	29,479	0	0	(65,558)	610,809
	<u>1,032,144</u>	<u>83,163</u>	<u>(21,856)</u>	<u>0</u>	<u>(105,985)</u>	<u>987,466</u>
<b>Expendable</b>						
<b>Endowments</b>						
Agouron	254,979	11,619	0	0	(25,840)	240,758
Grigg Fund	113,464	5,171	0	0	(11,499)	107,136
	<u>368,443</u>	<u>16,790</u>	<u>0</u>	<u>0</u>	<u>(37,339)</u>	<u>347,894</u>
<b>Total</b>						
<b>restricted funds</b>	<u>1,400,588</u>	<u>99,953</u>	<u>(21,856)</u>	<u>0</u>	<u>(143,324)</u>	<u>1,335,360</u>
<b>Total funds</b>	<u>3,432,052</u>	<u>219,385</u>	<u>(92,764)</u>	<u>0</u>	<u>(344,701)</u>	<u>3,213,972</u>

# The Max Perutz Fund (a company limited by guarantee)

## 12b Statement of Funds - prior year

	At 01/10/2020 £	Income £	Expenditure £	Transfers In/Out £	Investment Gains/ (Losses) £	At 30/09/2021 £
<b>General Fund</b>	682,594	237,960	(5,775)	0	182,151	1,096,930
<b>Designated Funds</b>						
Perutz Fund	258,184	13,576	(1,001)	0	60,531	331,290
Milstein Fund	499,477	22,643	(33,952)	0	109,134	597,302
AstraZeneca Lecture Series	3,020	148	0	0	708	3,876
Michael Neuberger Studentship	2,067	0	0	0	0	2,067
<b>Total</b>						
<b>Unrestricted funds</b>	<u>1,445,342</u>	<u>274,327</u>	<u>(40,729)</u>	<u>0</u>	<u>352,524</u>	<u>2,031,465</u>
<b>Restricted funds</b>						
Steitz (formerly Brenner) Postdoc Prize	5,929	15,863	(12,689)	0	2,035	11,138
Sangamo Aaron Klug Symposium	8,181	398	0	0	1,918	10,497
Jeanet Ramakrishnan	284,438	13,784	(1,039)	0	66,438	363,621
Jeanet Winter	504,171	24,523	0	0	118,194	646,888
	<u>802,719</u>	<u>54,568</u>	<u>(13,728)</u>	<u>0</u>	<u>188,585</u>	<u>1,032,144</u>
<b>Expendable Endowments</b>						
Agouron	198,725	9,666	0	0	46,588	254,979
Grigg Fund	88,432	4,301	0	0	20,731	113,464
	<u>287,157</u>	<u>13,967</u>	<u>0</u>	<u>0</u>	<u>67,319</u>	<u>368,443</u>
<b>Total</b>						
<b>restricted funds</b>	<u>1,089,876</u>	<u>68,535</u>	<u>(13,728)</u>	<u>0</u>	<u>255,904</u>	<u>1,400,588</u>
<b>Total funds</b>	<u>2,535,218</u>	<u>342,862</u>	<u>(54,456)</u>	<u>0</u>	<u>608,428</u>	<u>3,432,052</u>

### **Purposes of Designated Funds**

**The Max Perutz Fund** is used to fund prizes for young scientists and other approved purposes including for young scientists to attend Scientific Conferences of vocational interest to their studies.

**The Milstein Fund** funds a studentship or a fellowship to enable a young scientist from South America to undertake research at the LMB.

**AstraZeneca Lecture Series** funds a series of lectures given by leading national and international researchers in their biological and medical fields to an interested and open public audience.

**Michael Neuberger Studentship** was set up as a memorial to Dr Michael Neuberger who died in October 2013 to fund the training of PhD students in fundamental biological and medical research. Dr Neuberger worked as biochemist and immunologist at the Laboratory of Molecular Biology Cambridge, where he was also Deputy Director. The main fund is hosted by Trinity College Cambridge.

### **Purposes of Restricted Funds**

**The Steitz (formerly Brenner) LMB Postdoc Prize** is used to fund prizes for outstanding research by postdocs or investigators at the LMB.

**The Ramakrishnan Jeantet Fund** is a donation from the Louis Jeantet Foundation in respect of an award to Dr Venkatraman (Venki) Ramakrishnan for the Louis Jeantet Prize in 2017. Dr Ramakrishnan's work on the atomic structure and workings of the ribosome, which is responsible for protein synthesis within cells, has the potential to underpin the development of new drugs to help fight antibiotic resistance.

**The Winter Jeantet Fund** is a donation from the Louis Jeantet Foundation in respect of an award made to Dr Greg Winter originally in 1989, and managed until May 2012 within the private charitable funds of the MRC, until it was mutually agreed that the residue of the funds should be passed to the Max Perutz Fund. The fund is supporting work on a new technology that Dr Winter invented involving bicyclic peptides. The technology is very similar to that used to isolate human antibodies from the bacteria, with many of the same advantages. However the bicycles are much smaller and be chemically synthesised with ease. This technology potentially offers new opportunities to make novel therapeutics, but it is first necessary to explore the properties of the bicycles and optimise methods to make them. This fund relates to the funds of The Sir Gregory Jeantet Prize Fund, a charity linked to The Max Perutz Fund by the Charity Commission. See note 15 for more information.

**The Sangamo Aaron Klug Symposium Fund** is a donation from Sangamo Therapeutics Inc to fund the Aaron Klug Memorial Symposium; surplus funds are used for academic support.

The **Graduate Scientist/Postdoctoral Researcher Fund ('GSA/PAL fund')** was created in 2022 and is used to fund fund networking activities for graduate students and postdoctoral researchers.

### **Purposes of Expendable Endowments**

**The Agouron Fund** is a donation given by Agouron to assist in the long term funding of Dr Venki Ramakrishnan's research.

**The Grigg Fellowship Fund** promotes closer links between the Garvan Institute of Medical Research in Australia and the LMB.

**13a Analysis of Net Assets between Funds - current year**

	General Funds £	Designated Funds £	Restricted Funds £	Expendable Endowments Funds £	Total Funds £
Investments	905,695	761,401	876,286	308,724	2,852,106
Current Assets	127,229	104,824	111,358	39,170	382,581
Current Liabilities	(12,317)	(8,220)	(178)	0	(20,715)
<b>Net Assets at</b>					
<b>30 September 2022</b>	<u>1,020,607</u>	<u>858,005</u>	<u>987,466</u>	<u>347,894</u>	<u>3,213,972</u>

**13b Analysis of Net Assets between Funds - prior year**

	General Funds £	Designated Funds £	Restricted Funds £	Expendable Endowments Funds £	Total Funds £
Investments	925,858	788,789	871,176	310,982	2,896,807
Current Assets	174,476	152,895	163,768	57,461	548,600
Current Liabilities	(3,404)	(7,150)	(2,800)	0	(13,354)
<b>Net Assets at</b>					
<b>30 September 2022</b>	<u>1,096,930</u>	<u>934,535</u>	<u>1,032,144</u>	<u>368,443</u>	<u>3,432,052</u>

**14 Related parties and key management personnel**

The charity had no employees during the year (2021 - Nil) and as such there was no key management personnel remuneration (2021 - Nil).

The Medical Research Council Laboratory of Molecular Biology (LMB) funded the preparation of a book, 'Ahead of the Curve', to celebrate the contribution of women scientists at the LMB. The book was obtainable from the Max Perutz Fund on payment of a suggested donation at least sufficient to cover the cost of the book and postage. The costs paid for by the LMB for books distributed totalled £412 (2021 - £2,525).

The LMB also paid for the production of the Christmas cards sold by the Max Perutz Fund, generating revenue of £172 for the Fund (2021 - £169). The costs of the cards sold and funded by the LMB was £155 (2021 - £126).

There were no other related party transactions requiring disclosure during the year (2021 - none).

**15 Connected charities**

Since 6 January 2021 the Sir Gregory Winter Jeantet Prize Fund has been linked by the Charity Commission to the Max Perutz Fund. The details of the linked charity are as follows:

Charity registration no: 1129597-1

Governing document: User trusts

Charitable objective: see note 12 on page 23,

The Fund's assets were transferred to the Max Perutz Fund in May 2012 and classified as restricted funds. The movements on the Fund are as disclosed in note 12. The only income for the Fund in the year was dividends received; the Fund had no expenditure in the year.

